Please assess the completion status of the following clinical trial:

Trial Title: A Prospective, One-arm and Open Clinical Study of CM313 in the Treatment of Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 and above, male or female~* Conform to the diagnostic criteria of immune Thrombocytopenia (ITP)~* Diagnosis of ITP ≥3 months, and with a platelet count of \<30 X 109/L measured within 2 days prior to inclusion~* Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy including rituximab or TPORAs.~* The previous emergency treatment of ITP (e.g. methylprednisolone, platelet transfusion, IVIG transfusion) must be completed at least 2 weeks before the first administration~* Signed and dated written informed consent~* With normal hepatic and renal functions~* ECOG physical state score ≤ 2 points~* Cardiac function of the New York Society of Cardiac Function ≤ 2~* Patients receiving maintenance treatment (including corticosteroids (less than or equal to 0.5mg/kg prednisone), TPO receptor agonists, etc.) must have a stable dose at least 4 weeks before the first administration, and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of rituximab treatment was\>3 months；More than 6 months after splenectomy.~April 10, 2023 After approval by the Ethics Committee on , subjects no longer require platelet glycoprotein autoantibodies positivity upon enrollment.~Exclusion Criteria:~* Received any treatment of anti-CD38 antibody drug~* Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases;~* HIV positive;~* Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive;~* Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc.;~* At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled;~* Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis;~* Those who have received allogeneic stem cell transplantation or organ transplantation in the past;~* Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up;~* Patients whose toxic symptoms caused by pre-trial treatment have not disappeared;~* Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.);~* Patients with septicemia or other irregular severe bleeding;~* Patients taking antiplatelet drugs at the same time;~* Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (CM313) (Type: EXPERIMENTAL): 20 enrolled subjects: once a week x 8 doses

Based on this trial design, predict the completion outcome and termination type (if applicable).